HCP
COLL icon

Hexagon Capital Partners’s Collegium Pharmaceutical COLL Stock Holding History

Hexagon Capital Partners’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-98
Closed -$2.92K – 402
2025
Q1 		$2.92K Sell
98
-2
-2% -$61 ﹤0.01% 1305
2024
Q4 		$2.87K Buy
+100
New +$3.31K ﹤0.01% 1326

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Hexagon Capital Partners's COLL Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Collegium Pharmaceutical (COLL) in Q2 2025, closing a stake of 98 shares — an estimated $2.92K sold.

Hexagon Capital Partners first reported a position in COLL in Q4 2024 and held it in 2 quarters. The position peaked at $2.92K in Q1 2025. 223 funds tracked by Wall St. Rank hold COLL as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Collegium Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 98 Collegium Pharmaceutical shares in Q2 2025, an estimated $2.92K.
  • Hexagon Capital Partners first reported a position in Collegium Pharmaceutical in Q4 2024 and held it in 2 quarters.
  • Hexagon Capital Partners's Collegium Pharmaceutical position peaked at $2.92K in Q1 2025.
  • 223 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.